DNA-testing company 23andMe said on Monday that it was firing roughly 40% of its workforce, more than 200 people, as Chief ...

The therapeutic programs of 23andMe include an antibody that restores the ability of the immune system to kill cancer cells.

The struggling genetic testing company 23andMe says it will cut 40% of its workforce, or 200 jobs, as it fights for survival.

Bay Area genetic testing company 23andMe announced Monday that it plans to lay off 40% of its workforce as part of a broader restructuring effort aimed at cutting costs and refocusing the company on ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and ...

Prior to that, 23andMe’s independent directors—Roelof Botha, Patrick Chung, Sandra Hernández, Neal Mohan, Valerie Montgomery ...

"We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core ...

DNA commodification is no longer a future concern; it’s a present reality. Beyond charging users for their services, some ...

Holding “announced a business restructuring to streamline operations and reduce costs. In addition, 23andMe is discontinuing ...

Fortune spoke with USD professor of accounting Rick Warne on how 23andMe has never turned a profit and how former CFOs might help in building a sustainable business plan.

Her expertise is in personal finance and investing, and real estate. filadendron / Gety Images A staggered board of directors (also known as a classified board) is a board that is made up of ...